eligibility_summary
Incl: 18–75, advanced solid tumor post/unsuitable for standard tx, measurable (RECIST), ECOG 0–1, life ≥3 mo, adequate organ/coag, consent+tumor tissue, required washouts. Excl: recent other cancer, active/unstable CNS mets, immunocompromised, active serious infection incl HBV/HCV/syphilis, serious cardiopulmonary disease, prior EpCAM/CD3 bsAb or CAR‑T, unresolved tox, pregnancy/lactation or no contraception, substance abuse/psychiatric illness, non-epithelial tumors, allergy.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 1, single-arm dose-escalation/expansion of A-337 in adults with refractory/metastatic solid tumors of epithelial origin. Intervention: A-337, a recombinant anti-EpCAM×CD3 bispecific antibody (biological, IV infusion, 0.05–1.5 μg/kg/day). Mechanism of action: T-cell–redirecting bispecific that simultaneously binds EpCAM on tumor cells and CD3 on T lymphocytes, forming an immune synapse, activating the CD3/TCR complex, inducing T-cell cytotoxicity and cytokine release to lyse EpCAM+ cancer cells. Targets: EpCAM (TACSTD1) on epithelial tumor cells, CD3 on T cells, downstream T-cell activation pathways. Excludes nonepithelial tumors and prior EpCAM/CD3 bispecifics or CAR-T.